NYSE:GSK - GlaxoSmithKline Stock Price, News, & Analysis

Get Started

$37.68 +0.32 (+0.86 %)

(As of 12/13/2018 08:00 AM ET)

Previous Close$37.36

Today's Range$37.66 - $38.16

52-Week Range$34.83 - $42.36

Volume2.44 million shs

Average Volume3.68 million shs

Market Capitalization$92.65 billion

P/E Ratio13.08

Dividend Yield5.20%

Beta0.81

GlaxoSmithKline plc engages in the creation, discovery, development, manufacture, and marketing of vaccines, over-the-counter medicines, and health-related consumer products worldwide. It operates through four segments: Pharmaceuticals, Pharmaceuticals R&D, Vaccines, and Consumer Healthcare. The company offers pharmaceutical products comprising medicines in the therapeutic areas, such as respiratory, anti-virals, central nervous system, cardiovascular and urogenital, metabolic, anti-bacterials, dermatology, rare diseases, immuno-inflammation, and HIV, as well as vaccines. It also provides consumer healthcare products in wellness, oral health, nutrition, and skin health categories primarily under the Otrivin, Panadol, Fenistil, Lamisil, Breathe Right, Stiefel, Excedrin, Physiogel, Polident, parodontax, Poligrip, Sensodyne, Theraflu, and Voltaren brand names. The company offers its consumer healthcare products in the form of tablets, caplets, infant syrup drops, syrups, topical gels, nasal sprays, effervescents, lozenges, gum and trans-dermal patches, malted drinks and foods, and topical creams and non-medicated patches, as well as toothpastes, toothbrushes, mouth rinses, medicated mouthwashes, gels and sprays, denture adhesives, and denture cleansers. It has a discovery collaboration agreement with Kymera Therapeutics LLC; a collaboration agreement with InSysBio LLC to develop quantitative systems pharmacology model of asthma; and a strategic collaboration with NeuroMetrix, Inc. to develop and market Quell technology. GlaxoSmithKline plc was founded in 1715 and is headquartered in Brentford, the United Kingdom.

Receive GSK News and Ratings via Email

Sign-up to receive the latest news and ratings for GSK and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Stock Exchange NYSE

Industry Pharmaceutical preparations

Sub-IndustryN/A

SectorMedical

Current SymbolNYSE:GSK

Previous Symbol

CUSIPN/A

Webwww.gsk.com

Phone44-20-8047-5000

Debt

Debt-to-Equity Ratio6.66

Current Ratio0.95

Quick Ratio0.63

Price-To-Earnings

Trailing P/E Ratio13.08

Forward P/E Ratio12.64

P/E Growth2.51

Sales & Book Value

Annual Sales$38.89 billion

Price / Sales2.40

Cash Flow$3.8726 per share

Price / Cash Flow9.73

Book Value$1.81 per share

Price / Book20.82

Profitability

EPS (Most Recent Fiscal Year)$2.88

Net Income$1.97 billion

Net Margins5.78%

Return on Equity164.99%

Return on Assets9.96%

Miscellaneous

Employees99,349

Outstanding Shares2,479,930,000

Market Cap$92.65 billion

OptionableOptionable

GlaxoSmithKline (NYSE:GSK) Frequently Asked Questions

What is GlaxoSmithKline's stock symbol?

GlaxoSmithKline trades on the New York Stock Exchange (NYSE) under the ticker symbol "GSK."

How often does GlaxoSmithKline pay dividends? What is the dividend yield for GlaxoSmithKline?

GlaxoSmithKline announced a quarterly dividend on Thursday, November 1st. Stockholders of record on Friday, November 16th will be paid a dividend of $0.486 per share on Thursday, January 10th. This represents a $1.94 annualized dividend and a dividend yield of 5.16%. The ex-dividend date of this dividend is Thursday, November 15th. This is a positive change from GlaxoSmithKline's previous quarterly dividend of $0.46. View GlaxoSmithKline's Dividend History.

How were GlaxoSmithKline's earnings last quarter?

GlaxoSmithKline plc (NYSE:GSK) released its quarterly earnings results on Wednesday, October, 31st. The pharmaceutical company reported $0.83 earnings per share for the quarter, missing the Thomson Reuters' consensus estimate of $0.86 by $0.03. The pharmaceutical company earned $9.41 billion during the quarter, compared to analysts' expectations of $10.55 billion. GlaxoSmithKline had a return on equity of 164.99% and a net margin of 5.78%. View GlaxoSmithKline's Earnings History.

When is GlaxoSmithKline's next earnings date?

GlaxoSmithKline is scheduled to release their next quarterly earnings announcement on Wednesday, February 6th 2019. View Earnings Estimates for GlaxoSmithKline.

What price target have analysts set for GSK?

18 Wall Street analysts have issued 12 month price targets for GlaxoSmithKline's shares. Their predictions range from $36.95 to $47.00. On average, they expect GlaxoSmithKline's share price to reach $41.79 in the next year. This suggests a possible upside of 10.9% from the stock's current price. View Analyst Price Targets for GlaxoSmithKline.

What is the consensus analysts' recommendation for GlaxoSmithKline?

18 Wall Street analysts have issued "buy," "hold," and "sell" ratings for GlaxoSmithKline in the last year. There are currently 11 hold ratings and 7 buy ratings for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for GlaxoSmithKline.

Has GlaxoSmithKline been receiving favorable news coverage?

Media coverage about GSK stock has been trending neutral this week, InfoTrie Sentiment reports. The research group ranks the sentiment of news coverage by reviewing more than six thousand news and blog sources. The firm ranks coverage of public companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. GlaxoSmithKline earned a daily sentiment score of 0.3 on InfoTrie's scale. They also assigned headlines about the pharmaceutical company a news buzz of 2.0 out of 10, indicating that recent news coverage is very unlikely to have an impact on the company's share price in the near future.

Who are some of GlaxoSmithKline's key competitors?

Some companies that are related to GlaxoSmithKline include Pfizer (PFE), Roche Holdings AG Basel (RHHBY), Merck & Co., Inc. (MRK), Novartis (NVS), AbbVie (ABBV), Abbott Laboratories (ABT), Eli Lilly And Co (LLY), Sanofi (SNY), Novo Nordisk A/S (NVO), AstraZeneca (AZN), Bristol-Myers Squibb (BMY), Bayer (BAYRY), Shire (SHPG), Allergan (AGN) and Celgene (CELG).

Who are GlaxoSmithKline's key executives?

GlaxoSmithKline's management team includes the folowing people:

Ms. Emma Walmsley, CEO & Director (Age 48)
Mr. Simon P. Dingemans, CFO & Exec. Director (Age 54)
Mr. Jack Bailey, Pres of US Pharmaceuticals
Ms. Karenann K. Terrell, Chief Digital & Technology Officer (Age 57)
Dr. Hal V. Barron, Chief Scientific Officer, Pres of R&D and Director (Age 55)

Who are GlaxoSmithKline's major shareholders?

GlaxoSmithKline's stock is owned by a number of of retail and institutional investors. Top institutional investors include Dodge & Cox (1.94%), FMR LLC (0.77%), Fisher Asset Management LLC (0.56%), Renaissance Technologies LLC (0.41%), Morgan Stanley (0.17%) and Equity Investment Corp (0.12%). View Institutional Ownership Trends for GlaxoSmithKline.

Which institutional investors are selling GlaxoSmithKline stock?

GSK stock was sold by a variety of institutional investors in the last quarter, including Confluence Investment Management LLC, Primecap Management Co. CA, Envestnet Asset Management Inc., BlackRock Inc., Bruderman Asset Management LLC, Dodge & Cox, NWQ Investment Management Company LLC and Franklin Resources Inc.. View Insider Buying and Selling for GlaxoSmithKline.

Which institutional investors are buying GlaxoSmithKline stock?

GSK stock was bought by a variety of institutional investors in the last quarter, including Bank of New York Mellon Corp, Renaissance Technologies LLC, Eaton Vance Management, Morgan Stanley, Sio Capital Management LLC, FMR LLC, Diamond Hill Capital Management Inc. and Fisher Asset Management LLC. View Insider Buying and Selling for GlaxoSmithKline.

How do I buy shares of GlaxoSmithKline?

Shares of GSK can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is GlaxoSmithKline's stock price today?

One share of GSK stock can currently be purchased for approximately $37.68.

How big of a company is GlaxoSmithKline?

GlaxoSmithKline has a market capitalization of $92.65 billion and generates $38.89 billion in revenue each year. The pharmaceutical company earns $1.97 billion in net income (profit) each year or $2.88 on an earnings per share basis. GlaxoSmithKline employs 99,349 workers across the globe.

What is GlaxoSmithKline's official website?

The official website for GlaxoSmithKline is http://www.gsk.com.

How can I contact GlaxoSmithKline?

GlaxoSmithKline's mailing address is 980 GREAT WEST ROAD, BRENTFORD MIDDLESEX X0, TW8 9GS. The pharmaceutical company can be reached via phone at 44-20-8047-5000 or via email at [email protected]

MarketBeat Community Rating for GlaxoSmithKline (NYSE GSK)

Community Ranking:		1.8 out of 5 ()
Outperform Votes:		503 (Vote Outperform)
Underperform Votes:		863 (Vote Underperform)
Total Votes:		1,366

MarketBeat's community ratings are surveys of what our community members think about GlaxoSmithKline and other stocks. Vote "Outperform" if you believe GSK will outperform the S&P 500 over the long term. Vote "Underperform" if you believe GSK will underperform the S&P 500 over the long term. You may vote once every thirty days.

This page was last updated on 12/13/2018 by MarketBeat.com Staff

Featured Article: Return on Investment (ROI)